# Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face

> **NCT00986570** · PHASE3 · COMPLETED · sponsor: **Biolab Sanus Farmaceutica** · enrollment: 121 (actual)

## Conditions studied

- Skin Aging

## Interventions

- **BIOLOGICAL:** Botulinum Toxin A

## Key facts

- **NCT ID:** NCT00986570
- **Lead sponsor:** Biolab Sanus Farmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-06
- **Final completion:** 2010-11
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2015-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00986570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00986570, "Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00986570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*